A Study of Ramucirumab (LY3009806) in Healthy Participants
Status:
Completed
Trial end date:
2021-05-09
Target enrollment:
Participant gender:
Summary
This study evaluates a new formulation of ramucirumab, a drug approved for several types of
cancer.
In this study of healthy participants, a small amount of ramucirumab will be given by
injection either into a vein or just under the skin. Study doctors will measure the amount of
ramucirumab in the bloodstream.
Side effects and tolerability will be documented. The study will last for about 16 weeks for
each participant, including screening and follow up. Screening is required within 28 days
prior to entering the study.